Research
Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial
The Brief
- Researchers at the Linda Crnic Institute for Down Syndrome at the University of Colorado Anschutz ran a first-of-its-kind clinical trial.
- The trial was a phase 2 study of a medication that targets immune overactivity in people with Down syndrome.
- The medication reduced underlying inflammation in participants.
Why it matters
It offers early clinical evidence that immune overactivity, and the inflammation linked to it, can be targeted in people with Down syndrome, a condition that has had few tested treatment options.
Who’s affected
- people with Down syndrome
- clinicians and researchers studying Down syndrome and immune disorders
- #down syndrome
- #immunology
- #inflammation
- #clinical trial
- #phase 2
In a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune overactivity in people with Down syndrome reduced underlying inflammation and was…